Differentiating ALS Endophenotypes Using PBMC Biomarkers

TMT®MS3 Quantitative Proteomics

Goal – PBMC’s are the cellular component of blood and provide a rich source of circulating biomarkers. We performed unbiased, accurate quantitative proteomics to find PBMC-derived biomarkers differentiating bulbar and limb presentations of ALS.

Outcome - We have identified over 200 regulated peptides and 95 proteins in PBMC’s that show regulation between bulbar and limb endophenotypes and/or between fast and slow progressing disease. These are good candidates for further study towards an early stratification test for ALS patients to enable personalized treatment.

Collaborators - Dr. Andrea Malaspina, Queen Mary’s University, London, Professor Linda Greensmith, University College London

View all case studies